Cargando…
COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive car...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784620/ https://www.ncbi.nlm.nih.gov/pubmed/35152033 http://dx.doi.org/10.1016/j.euroneuro.2022.01.007 |
_version_ | 1784638781259776000 |
---|---|
author | Govind, Risha de Freitas, Daniela Fonseca Pritchard, Megan Khondoker, Mizanur Teo, James T. Stewart, Robert Hayes, Richard D. MacCabe, James H. |
author_facet | Govind, Risha de Freitas, Daniela Fonseca Pritchard, Megan Khondoker, Mizanur Teo, James T. Stewart, Robert Hayes, Richard D. MacCabe, James H. |
author_sort | Govind, Risha |
collection | PubMed |
description | Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive care treatment, and death, amongst patients taking antipsychotics with schizophrenia-spectrum disorders. Using the clinical records of South London and Maudsley NHS Foundation Trust, we identified 157 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders, were taking antipsychotics (clozapine or other antipsychotics) at the time of COVID-19 pandemic in the UK and had a laboratory-confirmed COVID-19 infection. The following health outcomes were measured: COVID-related hospitalisation, COVID-related intensive care treatment and death. We tested associations between clozapine treatment and each outcome using logistic regression models, adjusting for gender, age, ethnicity, neighbourhood deprivation, obesity, smoking status, diabetes, asthma, bronchitis and hypertension using propensity scores. Of the 157 individuals who developed COVID-19 while on antipsychotics (clozapine or other antipsychotics), there were 28% COVID-related hospitalisations, 8% COVID-related intensive care treatments and 8% deaths of any cause during the 28 days follow-up period. amongst those taking clozapine, there were 25% COVID-related hospitalisations, 7% COVID-related intensive care treatments and 7% deaths. In both unadjusted and adjusted analyses, we found no significant association between clozapine and any of the outcomes. Thus, we found no evidence that patients with clozapine treatment at time of COVID-19 infection had increased risk of hospitalisation, intensive care treatment or death, compared to non-clozapine antipsychotic-treated patients. However, further research should be considered in larger samples to confirm this. |
format | Online Article Text |
id | pubmed-8784620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87846202022-01-24 COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine Govind, Risha de Freitas, Daniela Fonseca Pritchard, Megan Khondoker, Mizanur Teo, James T. Stewart, Robert Hayes, Richard D. MacCabe, James H. Eur Neuropsychopharmacol Article Clozapine, an antipsychotic, is associated with increased susceptibility to infection with COVID-19, compared to other antipsychotics. Here, we investigate associations between clozapine treatment and increased risk of adverse outcomes of COVID-19, namely COVID-related hospitalisation, intensive care treatment, and death, amongst patients taking antipsychotics with schizophrenia-spectrum disorders. Using the clinical records of South London and Maudsley NHS Foundation Trust, we identified 157 individuals who had an ICD-10 diagnosis of schizophrenia-spectrum disorders, were taking antipsychotics (clozapine or other antipsychotics) at the time of COVID-19 pandemic in the UK and had a laboratory-confirmed COVID-19 infection. The following health outcomes were measured: COVID-related hospitalisation, COVID-related intensive care treatment and death. We tested associations between clozapine treatment and each outcome using logistic regression models, adjusting for gender, age, ethnicity, neighbourhood deprivation, obesity, smoking status, diabetes, asthma, bronchitis and hypertension using propensity scores. Of the 157 individuals who developed COVID-19 while on antipsychotics (clozapine or other antipsychotics), there were 28% COVID-related hospitalisations, 8% COVID-related intensive care treatments and 8% deaths of any cause during the 28 days follow-up period. amongst those taking clozapine, there were 25% COVID-related hospitalisations, 7% COVID-related intensive care treatments and 7% deaths. In both unadjusted and adjusted analyses, we found no significant association between clozapine and any of the outcomes. Thus, we found no evidence that patients with clozapine treatment at time of COVID-19 infection had increased risk of hospitalisation, intensive care treatment or death, compared to non-clozapine antipsychotic-treated patients. However, further research should be considered in larger samples to confirm this. The Authors. Published by Elsevier B.V. 2022-03 2022-01-24 /pmc/articles/PMC8784620/ /pubmed/35152033 http://dx.doi.org/10.1016/j.euroneuro.2022.01.007 Text en © 2022 The Authors. Published by Elsevier B.V. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Govind, Risha de Freitas, Daniela Fonseca Pritchard, Megan Khondoker, Mizanur Teo, James T. Stewart, Robert Hayes, Richard D. MacCabe, James H. COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title | COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title_full | COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title_fullStr | COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title_full_unstemmed | COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title_short | COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
title_sort | covid-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784620/ https://www.ncbi.nlm.nih.gov/pubmed/35152033 http://dx.doi.org/10.1016/j.euroneuro.2022.01.007 |
work_keys_str_mv | AT govindrisha covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT defreitasdanielafonseca covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT pritchardmegan covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT khondokermizanur covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT teojamest covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT stewartrobert covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT hayesrichardd covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine AT maccabejamesh covidrelatedhospitalizationintensivecaretreatmentandallcausemortalityinpatientswithpsychosisandtreatedwithclozapine |